Tinengotinib showed encouraging preliminary antitumor activity in heavily pretreated patients with a variety of advanced solid tumors including cholangiocarcinoma, HR-positive/HER2-negative breast cancer, TNBC, and CRPC. Here, ERBB2 is linked to breast carcinoma.